Antiarrhythmic efficacy and hemodynamic effects of cibenzoline in patients with nonsustained ventricular tachycardia and left ventricular dysfunction.

Seals, A. Allen; Haider, Rochelle; León, Carlos; Francis, Marilyn; Young, James B.; Roberts, Robert; Pratt, Craig M.

doi:10.1161/01.cir.75.4.800

Cited by 13 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The selection of cibenzoline dose based only on renal function seems to have a risk of toxicity in patients with high BNP values, namely severe heart-failure patients, therefore, careful administration of cibenzoline is required for patients with a low left ventricular ejection fraction. 33 A precise nomogram has been developed for cibenzoline therapy in Japanese patients with impaired renal function, 34 but a further nomogram should be developed based on a pharmacokinetic and pharmacodynamic study for appropriate dosing of cibenzoline in patients with heart failure, because cibenzoline therapy is not the first selected regimen in patients with heart failure because of the large possibility of cardiac depression.…”

Section: Discussionmentioning

confidence: 99%

Heart Failure Elevates Serum Levels of Cibenzoline in Arrhythmic Patients

Kotake

Takada

Komamura

et al. 2006

Circ J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Heart Failure Elevates Serum Levels of Cibenzoline in Arrhythmic Patients

Kotake

Takada

Komamura

et al. 2006

Circ J

View full text Add to dashboard Cite

Effects of Hypoxia on the Use‐Dependent Inhibition of Conduction Velocity Induced by Cibenzoline in Guinea Pig Ventricular Myocardium

Hasegawa

Watanabe

Kaneda

et al. 1993

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The use-dependent effects of cibenzoline, a new anti-arrhythmic drug, on the maximal rate of rise (Vmax) of the action potential and on conduction velocity, and their corresponding recovery kinetics were studied in isolated papillary muscles of guinea pigs under normal and hypoxic conditions. Standard microelectrode techniques were applied to monitor the action potential of the muscles and their conduction. Under control conditions, the amount of use-dependent block of Vmax, conduction velocity, and square of conduction velocity, induced by 10 mumol/L cibenzoline were 26.5 +/- 3.9, 13.8 +/- 1.4, and 25.6 +/- 2.4%, respectively; under hypoxic conditions, these values increased to 32.3 +/- 4.8, 19.7 +/- 1.2, and 35.5 +/- 2.0%, respectively. In the presence of 10 mumol/L cibenzoline, the mean values of time constants for the onset of the use-dependent inhibition of Vmax, conduction velocity, and the square of conduction velocity, during a 2-Hz stimulation, were 3.65 +/- 0.27, 2.77 +/- 0.33, and 2.56 +/- 0.26 seconds, respectively. Under hypoxic conditions, these values changed to 5.10 +/- 0.96, 3.05 +/- 0.44, and 2.84 +/- 0.39 seconds, respectively. The recovery time constants averaged 14.72 +/- 4.08 seconds (for Vmax), 22.23 +/- 3.78 seconds (for conduction velocity), and 23.17 +/- 13.38 seconds (for the square of conduction velocity) in the presence of 10 mumol/L cibenzoline, and 17.19 +/- 8.59 seconds (for Vmax), 15.77 +/- 2.37 seconds (for conduction velocity), and 16.82 +/- 2.61 seconds (for the square of conduction velocity) under hypoxic conditions.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Intravenous cibenzoline in the management of acute supraventricular tachyarrhythmias

Bru

Cointe

Paganelli

et al. 1995

Cardiovasc Drug Ther

View full text Add to dashboard Cite

Intravenous cibenzoline was evaluated in 37 patients with acute supraventricular tachyarrhythmias and a ventricular rate > 120 beats/min. The presenting arrhythmia was atrial fibrillation in 15 patients, atrial flutter in 5, ectopic atrial tachycardia in 11, and paroxysmal atrioventricular (AV) junctional reentrant tachycardia in 6 patients. Intravenous cibenzoline was administered as a bolus given over 2 minutes, at a dose of 1 mg/kg in the first 26 patients and 1.2 mg/kg in the subsequent 11 patients, 15 minutes following failure of placebo (isotonic glucose). The results were evaluated 15 minutes after the intravenous injection. Restoration of sinus rhythm was obtained in 3 out of 6 patients with paroxysmal AV junctional tachycardia (50%) and in 7 out of 31 patients (23%) with atrial tachyarrhythmias (5 out of 15 patients with atrial fibrillation and 2 out of 16 patients with ectopic atrial tachycardia or atrial flutter). Five additional patients with atrial tachyarrhythmias had slowing of ventricular rate below 100 beats/min. Therefore, a satisfactory result, that is, restoration of sinus rhythm or slowing of ventricular rate, occurred in 15 patients (40.5%). Side effects were transient, including visual disturbance (one patient), asymptomatic widening of QRS complex (three patients), incessant reciprocating tachycardia (one patient), and acceleration of ventricular rate (eight patients), resulting in 1:1 flutter, with poor tolerance in two patients.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Antiarrhythmic efficacy and hemodynamic effects of cibenzoline in patients with nonsustained ventricular tachycardia and left ventricular dysfunction.

Cited by 13 publications

References 32 publications

Heart Failure Elevates Serum Levels of Cibenzoline in Arrhythmic Patients

Heart Failure Elevates Serum Levels of Cibenzoline in Arrhythmic Patients

Effects of Hypoxia on the Use‐Dependent Inhibition of Conduction Velocity Induced by Cibenzoline in Guinea Pig Ventricular Myocardium

Intravenous cibenzoline in the management of acute supraventricular tachyarrhythmias

Contact Info

Product

Resources

About